News & Updates

Treatment with tofacitinib is both safe and effective in a real-world setting, as shown in a Canada study, in which a third of patients with ulcerative colitis (UC) achieved clinical remission with few serious adverse events. However, nearly half of them have lost response following dose de-escalation, and this is only partially recaptured with re-escalation.

Applying a single dose of the novel vaginal film ZB-06 before intercourse is safe and appears to prevent sperm from reaching the egg, according to the results of a phase I, proof-of-concept trial.

The combination of camrelizumab plus apatinib and temozolomide appears to be beneficial in the first-line treatment of advanced acral melanoma, with the majority of the patients showing response and an acceptable safety profile, according to the results of a phase II study.

An increased risk of overdose events in the next 24 weeks is seen in patients with opioid use disorder seeking medication treatment who fail to initiate or discontinue medication and those who report using benzodiazepine at baseline, reports a study.

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.